AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$UTHR

ROTHBLATT MARTINE A sold $4.5M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $477.42 ($472.05–$486.77, $4.54M total) across 12 trades on 2026-09-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 30, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short‑term sentiment assessment.

02

Market read

First public disclosure of a multi‑million dollar insider sale; modest relevance for traders monitoring insider activity.

03

What to watch

Potential tax planning or liquidity needs unrelated to company outlook.

Relevance 5/10Novelty 5/10Timing: after-hours filing today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

Chairperson & CEO Martine Rothblatt sold $4.5M of shares via a 10b5-1 plan, reducing her stake to 324,443 shares.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

The sale is sizable for a micro‑cap biotech and was executed through a pre‑arranged plan, suggesting a neutral to slightly negative impact.

Market effects

Sector

Minimal; the sale does not affect the broader biotech sector.

Regional

None; impact confined to UTHR shareholders.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

The sale could be purely portfolio diversification and not reflect company fundamentals.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company developing cell and gene therapies.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min